Background: Radioiodine remnant ablation (RRA) has traditionally been one of the
cornerstones of differentiated thyroid cancer (DTC) treatment. The decision to use RRA in …

Context: There is uncertainty over the dose of 131I required for thyroid remnant ablation.
Most previous studies have been inadequately powered to establish the best fixed dose of …

Objective To describe the risk of structural disease recurrence in a cohort of patients with
differentiated thyroid cancer selected for treatment with either thyroid lobectomy or total …

Radioactive iodine remnant ablation (RRA) is used to destroy residual normal thyroid tissue
after complete gross surgical resection of papillary or follicular thyroid cancer. The article …

Radioactive iodine remnant ablation destroys residual thyroid tissue after surgical resection
of papillary or follicular thyroid cancer. We systematically reviewed 1543 English references …

Objective (a) To compare the efficacy of low-activity (2 GBq; 54 mCi) 131I ablation using l-
thyroxine withdrawal or rhTSH stimulation, and (b) to assess the influence of thyroid …

Management recommendations for differentiated thyroid cancer are evolving. Total
thyroidectomy is the backbone of curative-intent therapy, with radioiodine ablation (RAI) of …

Background: Multiple studies have demonstrated successful radioactive iodine remnant
ablation (RRA) following preparation with recombinant human thyroid stimulating hormone …

Context: Radioiodine ablation of the thyroid remnant after thyroidectomy is commonly
performed in the management of patients with differentiated thyroid cancer. Although many …

Background: Radioactive iodine (RAI) remnant ablation has been used to eliminate normal
thyroid tissue and may also facilitate monitoring for persistent or recurrent thyroid carcinoma …